Fulgent Genetics (FLGT) EV to EBITDA (2016 - 2026)

Fulgent Genetics has disclosed EV to EBITDA across 11 years of filings, most recently posting 8.37 for Q2 2026.

• In Q2 2026, EV to EBITDA rose 46.88% year-over-year to 8.37; the TTM figure through Jun 2026 stood at 3.49 (up 18.32% YoY), while the FY2025 annual figure was 5.22, down 25.4% from the prior year.
• EV to EBITDA came in at 8.37 for Q2 2026 at Fulgent Genetics, down from 5.11 in the prior quarter.
• In the past five years, EV to EBITDA ranged from a high of 1604.35 in Q3 2022 to a low of 950.29 in Q4 2025.
• Average EV to EBITDA over 5 years is 118.53, with a median of 12.23 recorded in 2024.
• Year-over-year, EV to EBITDA jumped 11406.1% in 2022 and slumped 4887.02% in 2025.
• Over 5 years, EV to EBITDA stood at 9.67 in 2022, then jumped by 70.57% to 2.85 in 2023, then slumped by 569.22% to 19.06 in 2024, then tumbled by 4887.02% to 950.29 in 2025, then surged by 99.12% to 8.37 in 2026.
• Per Business Quant data, the three most recent EV to EBITDA figures were 8.37 in Q2 2026, 5.11 in Q1 2026, and 950.29 in Q4 2025.